chymotrypsin

Trade name: zolyse

Biologicalapproved

Approved

May 29, 1959

Chymotrypsin (EC 3.4.21.1, chymotrypsins A and B, alpha-chymar ophth, avazyme, chymar, chymotest, enzeon, quimar, quimotrase, alpha-chymar, alpha-chymotrypsin A, alpha-chymotrypsin) is a digestive enzyme component of pancreatic juice acting in the duodenum, where it performs proteolysis, the breakdown of proteins and polypeptides. Chymotrypsin preferentially cleaves peptide amide bonds where the side chain of the amino acid N-terminal to the scissile amide bond (the P1 position) is a large hydrophobic amino acid (tyrosine, tryptophan, and phenylalanine). These amino acids contain an aromatic ring in their side chain that fits into a hydrophobic pocket (the S1 position) of the enzyme. It is activated in the presence of trypsin. The hydrophobic and shape complementarity between the peptide substrate P1 side chain and the enzyme S1 binding cavity accounts for the substrate specificity of this enzyme. Chymotrypsin also hydrolyzes other amide bonds in peptides at slower rates, particularly those containing leucine at the P1 position. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 4 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2

Earliest trial started Jun 8, 2022 (NCT06139835)

Timeline

1950s

  1. May 29, 1959

    Earliest FDA Approval

  2. May 29, 1959

    Johnson and Johnson — NDA Secondary Org

  3. Jul 8, 1959

    Alcon — First NDA Organization

  4. Jul 8, 1959

    Alcon — NDA Secondary Org

  5. Jul 8, 1959

    Alcon — NDA Organization

1970s

  1. Mar 27, 1979

    Novartis — NDA Secondary Org

Indications

Mechanism of action

  • PolypeptidesPROTEOLYTIC ENZYME

    Polypeptides proteolytic enzyme

    To replace endogenous digestive enzyme chymotrypsin, which protects against pancreatitis, in cases where loss of function variants have been identified in the CTRC gene; preferential cleavage: leu-|-xaa, tyr-|-xaa, phe-|-xaa, met-|-xaa, trp-|-xaa, gln-|-xaa, asn-|-xaa.

Approval history

  • approvedMay 29, 1959

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Discontinued

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • alpha chymar
  • alpha chymar
  • alpha-chymar
  • catarase
  • chymar
  • chymoral
  • chymoral
  • chymoral fte
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin
  • chymotrypsin - trypsin
  • chymotrypsin, trypsin drug combination
  • chypsin
  • deanase dc
  • ec 3.4.21.1
  • zolyse
  • zolyse
  • zonulysin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06562816Phase 4Aug 16, 2024Dow University of Health Sciences, Duke University
NCT06164509Phase 4Dec 20, 2023Ain Shams University
NCT06139835N/AJun 8, 2022Pontis Biologics, Inc.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ain Shams UniversityAcademic/Hospital1112023
Dow University of Health SciencesAcademic/Hospital1112024
Duke UniversityAcademic/Hospital1012024
Pontis Biologics, Inc.For profit1112022
4 organizations
Page 1 / 1

Marketing (5)

OrganizationOrg typeRelationshipDate
AlconFor profitNDA2Jul 8, 1959
AlconFor profitNDAJul 8, 1959
CibaFor profitNDA2
Johnson and JohnsonFor profitNDA2May 29, 1959
NovartisFor profitNDA2Mar 27, 1979